Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
SLNO

SLNO - Soleno Therapeutics Inc Stock Price, Fair Value and News

$52.79+0.03 (+0.06%)
Market Closed

52/100

SLNO

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

52/100

SLNO

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

SLNO Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

SLNO Price Action

Last 7 days

0.2%

Last 30 days

75.6%

Last 90 days

26.9%

Trailing 12 Months

-28.3%

SLNO RSI Chart

SLNO Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

SLNO Valuation

Market Cap

2.7B

Price/Earnings (Trailing)

130.38

Price/Sales (Trailing)

14.3

EV/EBITDA

98.52

Price/Free Cashflow

58.29

SLNO Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

SLNO Fundamentals

SLNO Revenue

Revenue (TTM)

190.4M

SLNO Earnings

Earnings (TTM)

20.9M

Earnings Growth (Yr)

177.45%

Earnings Growth (Qtr)

66.68%

SLNO Profitability

Operating Margin

98.57%

EBT Margin

10.97%

Return on Equity

4.64%

Return on Assets

3.71%

Free Cashflow Yield

1.72%

SLNO Investor Care

Shares Dilution (1Y)

12.58%

Diluted EPS (TTM)

0.33

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20250114.8M152.6M190.4M
20171.3M39.1M76.9M0
2016812.6K1.1M1.2M1.5M
20152.3M1.7M1.0M387.6K
20130003.0M
Get all data in R, Python etc through our Historical Stock Data APIs

About Soleno Therapeutics Inc

SLNO
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
 CEO
 WEBSITEhttps://soleno.life
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES25

Soleno Therapeutics Inc Frequently Asked Questions

SLNO is the stock ticker symbol of Soleno Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Tue Apr 28 2026, market cap of Soleno Therapeutics Inc is 2.72 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Tue Apr 28 2026, SLNO's PE ratio (Price to Earnings) is 130.38 and Price to Sales (PS) ratio is 14.3. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SLNO PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Soleno Therapeutics Inc has provided -0.054 (multiply by 100 for percentage) rate of return.